Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 4/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20259156 | 0.70 | CES2 (0.40) | KDM4EALDH1A1HPGDHSD17B10CFTR | |
| SCHEMBL22620411 | 0.69 | PDE2A (0.41) | KDM4EALDH1A1HPGDHSD17B10PDE2A | |
| SCHEMBL16488279 | 0.67 | CES2 (0.46) | KDM4EALDH1A1HPGDHSD17B10PDE2A | |
| SCHEMBL22620302 | 0.65 | ADRA2A (0.40) | KDM4EALDH1A1HPGDHSD17B10PDE2A | |
| SCHEMBL20052480 | 0.65 | L3MBTL1 (0.44) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL20274108 | 0.65 | KIF11 (0.43) | KDM4EALDH1A1HSD17B10CYP2C19MAPK1 | |
| SCHEMBL21348480 | 0.65 | MGLL (0.31) | CES2 | |
| SCHEMBL19139880 | 0.63 | CES2 (0.42) | KDM4EALDH1A1HPGDHSD17B10CFTR | |
| SCHEMBL16023620 | 0.63 | HRH4 (0.36) | KDM4EPDE2A | |
| SCHEMBL20274085 | 0.63 | HRH4 (0.38) | KDM4EPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793564-B2 | Amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190276449-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793564-B2 | Amino acid compounds and methods of use | ITGB6, ITGA6, ITGA5 | KDM4E 3239/4885ALDH1A1 3834/4885HPGD 3372/4885 |
| US-20190276449-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | KDM4E 3239/4885ALDH1A1 3834/4885HPGD 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.